CIK 0001798749
- Emerging growth company
Jade Biosciences, Inc.
Sign in to watch- Ticker
- JBIO
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 831377888
- Phone
- +1 781-312-3013
- Business address
- 221 CRESCENT ST., BUILDING 23, SUITE 105, WALTHAM, MA, 02453
- Former names
- Aerovate Therapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 84 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-06-25 | Eisner Mark Director | Grant or award · Stock Option (Right to Buy) | +47,675 | 47,675 | ||
| 2026-06-09 | CAIN CHRISTOPHER W. Director | Grant or award · Stock Option (Right to Buy) | +34,843 | 34,843 | ||
| 2026-06-09 | DOBMEIER ERIC Director | Grant or award · Stock Option (Right to Buy) | +34,843 | 34,843 | ||
| 2026-06-09 | Klein Lawrence Otto Director | Grant or award · Stock Option (Right to Buy) | +34,843 | 34,843 | ||
| 2026-06-09 | Lavelle Erin Director | Grant or award · Stock Option (Right to Buy) | +34,843 | 34,843 | ||
| 2026-06-09 | Fairmount Funds Management LLC Director | Grant or award · Stock Option (Right to Buy) | +34,843 | 34,843 | ||
| 2026-02-12 | Dahms Bradford D. Chief Financial Officer | Grant or award | +37,813 | 37,813 | ||
| 2026-02-12 | Dahms Bradford D. Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +226,875 | 226,875 | ||
| 2026-02-12 | Balta Elizabeth See Remarks | Grant or award | +28,125 | 28,125 | ||
| 2026-02-12 | Balta Elizabeth See Remarks | Grant or award · Stock Option (Right to Buy) | +168,750 | 168,750 | ||
| 2026-02-12 | Frohlich Tom Chief Executive Officer | Grant or award | +78,750 | 86,331 | ||
| 2026-02-12 | Frohlich Tom Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +472,500 | 472,500 | ||
| 2026-02-12 | King Andrew James See Remarks | Grant or award | +41,250 | 386,113 | ||
| 2026-02-12 | King Andrew James See Remarks | Grant or award · Stock Option (Right to Buy) | +247,500 | 247,500 | ||
| 2025-10-06 | Fairmount Funds Management LLC Director | Grant or award | +1,333,126 | $9.14 | $12.2M | 1,897,677 |
| 2025-10-06 | Fairmount Funds Management LLC Director | Grant or award · Pre-Funded Warrant (Right to Buy) | +855,047 | $9.14 | $7.8M | 855,047 |
| 2025-07-14 | Dahms Bradford D. Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +526,000 | 526,000 | ||
| 2025-05-16 | Frohlich Tom Chief Executive Officer | Purchase | +6,000 | $7.40 | $44K | 6,000 |
| 2025-04-29 | Fairmount Funds Management LLC Director | Grant or award · Stock Option (Right to Buy) | +23,017 | 23,017 | ||
| 2025-04-29 | Lavelle Erin Director | Grant or award · Stock Option (Right to Buy) | +23,017 | 23,017 |
Page 1 of 16 · 315 trades